Research library
The research library
Every primary source behind a claim on this site, tier-graded for provenance and tagged for the strength of the evidence it carries.
- Sources indexed
- 221
- Peptides covered
- 44
- Tier 1 share
- 0%
- Matching filter
- 3
F·Filter
Reset allT2·Peer-secondary literature
Peer-reviewed reviews and cohort/observational work — context, not bedrock.
2 sources
- 2021Opinionmoderate
The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers
Wakabayashi H, Arai H, Inui A · Journal of Cachexia, Sarcopenia and Muscle
Anamorelin received Japanese PMDA approval on 11 December 2020 for cancer cachexia in four indications — the first regulatory approval for cancer cachexia globally and the first GHSR-1a-agonist approval for a muscle-wasting indication, on essentially the same data the EMA had rejected in 2017.
- 2016Opinionmoderate
Welcome to the ICD-10 code for sarcopenia
Anker SD, Morley JE, von Haehling S · Journal of Cachexia, Sarcopenia and Muscle
The October 2016 assignment of ICD-10-CM code M62.84 separated sarcopenia from cachexia, disuse atrophy, and inflammatory myopathy — the bureaucratic act that formalized sarcopenia as a discrete clinical entity rather than an aspect of frailty or aging in general.
T3·Expert-primary work
Domain-expert primary sources outside the journal pipeline — lectures, podcasts, position papers.
1 source
- 2005Opinionanecdotaln=300
The effect of AOD9604 on weight loss in obese adults: results of a randomized, double-blind, placebo-controlled, multicenter study
Herd C, Wittert G, Caterson L, +6 · Obesity Research (NAASO Annual Meeting conference proceedings)
The Phase IIa AOD-9604 data — the 1 mg oral dose producing roughly 2.6–2.8 kg weight loss versus 0.8 kg on placebo across 12 weeks in 300 obese adults — was presented as a NAASO conference abstract in 2005 and never developed into a peer-reviewed full-paper publication. The marketing literature in 2026 still cites it as primary evidence.